Article Figures & Data
Figures
- FIGURE 1.
Cadmium zinc telluride–based molecular breast imaging camera. (Reprinted with permission of (79).)
- FIGURE 2.
Mammogram (left) and molecular breast imaging scan (right) of same patient. Twenty-millimeter cancer (red box) can be seen on both images, but only molecular breast image (using sestamibi) shows additional 10-mm lesion. (Reprinted with permission of (80).)
- FIGURE 3.
McLarty and Reilly showed that micro-SPECT/CT of HER2-overexpressing breast cancer could be achieved using 111In-labeled pertuzumab. Because this domain is different from that to which Herceptin binds, it should be possible to perform this type of molecular imaging of HER2 expression even in patients being treated with trastuzumab. (Courtesy of Raymond Reilly, University of Toronto.)
- FIGURE 4.
Images of peptide-based agent (99mTc-NC100692) using both dedicated breast imaging system and conventional scintimammography. Red boxes delineate 7-mm invasive ductal carcinoma that is barely visible on scintimammography (arrow). (Reprinted with permission of (16).)
- FIGURE 5.
18F-FDG positron emission mammography scan of 40-y-old woman whose first mammogram showed area of increased density in left inferior breast. Positron emission mammography scan shows invasive ductal carcinoma in both breasts. (Courtesy of Jacquelyn Jordan Gray, Naviscan, Inc.)
- FIGURE 6.
Small-animal PET images of 18F-labeled Affibody for HER2 in mice bearing SKOV-3 tumors. (Reprinted with permission of (33).)
- FIGURE 7.
Small-animal MRI and PET scans of subcutaneous αvβ3-expressing glioma xenografts administered coated iron oxide multimodal probe derivatized with cyclic arginine-glycine-aspartic (RGD) acid peptides and DOTA chelating groups. Images involving targeted agent, control particles, and specific blocking experiments in nude mice are shown.
- FIGURE 8.
Ultrasound image of mouse embryo. (Courtesy of Stuart Foster, Sunnybrook Health Sciences Centre.)
- FIGURE 9.
Positron emission mammography–guided biopsy based on uptake of 18F-FDG. (Courtesy of Jacquelyn Jordan Gray, Naviscan, Inc.)
- FIGURE 10.
Fluorous labeling method. After treatment of fluorine-rich starting material with radioiodine and oxidant, unreacted starting material and fluorous byproducts can be separated from product using solid-phase extraction cartridge containing fluorine-rich bonded phase (fluorous solid-phase extraction, or FSPE). (Reprinted with permission of (70).)
